SCHEMBL20567009

SCHEMBL20567009

Clc1ccc(Oc2cc(Cl)cc(CN3CCNCC3)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.52
ALDH1A1 P00352 1/20 0.52
FAAH O00519 3/20 0.52
LMNA P02545 1/20 0.50
SIGMAR1 Q99720 1/20 0.47
CXCR4 P61073 5/20 0.44
MEN1 O00255 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
ADRA2C P18825 1/20 0.44
CCR2 P41597 1/20 0.44
CXCL12 P48061 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
SCN9A Q15858 1/20 0.43
S1PR5 Q9H228 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27883542 0.88 LTA4H (0.61) LTA4HALDH1A1FAAHLMNASIGMAR1
SCHEMBL23434840 0.88 FAAH (0.48) ALDH1A1FAAHSIGMAR1CXCR4MEN1
Hydrochloric Acid SCHEMBL2232357 0.87 LTA4H (0.62) LTA4HALDH1A1FAAHLMNASIGMAR1
Hydrochloric Acid SCHEMBL2451705 0.84 ALDH1A1 (0.70) LTA4HALDH1A1FAAHLMNASIGMAR1
SCHEMBL626347 0.80 L3MBTL1 (0.61) SIGMAR1CXCR4MEN1CHRM2CHRM1
SCHEMBL20570341 0.79 FAAH (0.67) ALDH1A1FAAHLMNAS1PR5
Hydrochloric Acid SCHEMBL17062037 0.78 L3MBTL1 (0.59) SIGMAR1CXCR4MEN1CHRM2CHRM1
SCHEMBL5734193 0.78 SIGMAR1 (0.68) ALDH1A1SIGMAR1CXCR4MEN1CHRM2
SCHEMBL208118 0.78 SIGMAR1 (0.68) ALDH1A1SIGMAR1CXCR4MEN1CHRM2
Hydrochloric Acid SCHEMBL2921947 0.77 CXCR4 (0.68) ALDH1A1SIGMAR1CXCR4MEN1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
CN-116473965-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2025-03-18 CN disclosed
EP-3634404-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2024-11-20 EP disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
CN-110678177-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-06-13 CN disclosed
EP-3630744-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-08 EP disclosed
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2020-03-19 US disclosed
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2020-03-19 US disclosed
CN-110678177-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 CN disclosed
CN-110678456-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 CN disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
WO-2018217809-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 US disclosed
WO-2018217805-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL LTA4H 205/4885ALDH1A1 2448/4885FAAH 33/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL LTA4H 205/4885ALDH1A1 2448/4885FAAH 33/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL LTA4H 183/4885ALDH1A1 2260/4885FAAH 32/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL LTA4H 205/4885ALDH1A1 2448/4885FAAH 33/4885
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS MAGI3, MAG, PYM1 LTA4H 1738/4885ALDH1A1 4019/4885FAAH 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.